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MaMyocardial ﬁbrosis impairs cardiac function, in addition to facilitating arrhythmias and ischemia, and thus inﬂuences
the evolution and outcome of cardiac diseases. Its assessment is therefore clinically relevant. Although tissue biopsy
is the gold standard for the diagnosis of myocardial ﬁbrosis, a number of circulating biomarkers have been proposed for
the noninvasive assessment of this lesion. A review of the published clinical data available on these biomarkers shows
that most of them lack proof that they actually reﬂect the myocardial accumulation of ﬁbrous tissue. In this “call to
action” article, we propose that this absence of proof may lead to misinterpretations when considering the incremental
value provided by the biomarkers with respect to traditional diagnostic tools in the clinical handling of patients. We thus
argue that strategies are needed to more strictly validate whether a given circulating biomarker actually reﬂects histo-
logically proven myocardial ﬁbrosis before it is applied clinically. (J Am Coll Cardiol 2015;65:2449–56) © 2015 by the
American College of Cardiology Foundation.T he search for biomarkers of structural myocar-dial remodeling with potential usefulness forthe clinical handling of cardiac diseases has
been a proliﬁc ﬁeld in the last few years. The investiga-
tion of circulating biomarkers for myocardial ﬁbrosis, 1
key component of structural myocardial remodeling,
has been accelerating at a remarkable pace. These in-
vestigations have deluged the clinical and research
communities, however, with numerous candidates,
few of which are likely to survive as useful clinical tools
in terms of diagnosis, prognosis, and therapy moni-
toring (1,2). One possible explanation for this failure is
that most of the proposed biomarkers lack proof thatm the *Program of Cardiovascular Diseases, Centre for Applied Medical
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changes in collagen tissue characteristic of myocardial
ﬁbrosis. The present article focused on the necessity of
accurately histologically validating each circulating
molecule before it can be considered as a true
biomarker of myocardial ﬁbrosis in cardiac patients.
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ABBR EV I A T I ON S
AND ACRONYMS
CIVF = myocardial collagen
type I volume fraction
CIIIVF = myocardial collagen
type III volume fraction
CVF = collagen volume fraction
DCM = dilated cardiomyopathy
HF = heart failure
HHD = hypertensive heart
disease
LV = left ventricular
LVAD = left ventricular
assist device
MMP = matrix
metalloproteinase
PICP = carboxy-terminal
propeptide of procollagen
type I
PIIINP = amino-terminal
propeptide of procollagen
type III
TGF = transforming
growth factor
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2450accumulation within the myocardium of an
excess of collagen type I and type III ﬁbers
that characterizes ﬁbrosis (Figure 1). Two
distinct patterns of collagen accumulation
can be distinguished in myocardial ﬁbrosis
(3): focal, to replace dead cardiomyocytes
and form scars (replacement ﬁbrosis), and
diffuse, which occurs in the interstitial and
perivascular space without notable cell loss
(reactive ﬁbrosis). Although both patterns are
observed in the heart after acute myocardial
infarction, the second affects a large portion
of the elderly population, and it is often a
common feature of chronic cardiac diseases
such as hypertensive heart disease, aortic
valve stenosis, diabetic cardiomyopathy, and
hypertrophic cardiomyopathy. The present
review therefore focuses on reactive myo-
cardial ﬁbrosis.
The composition of ﬁbrotic tissue in reac-
tive myocardial ﬁbrosis is characterized by an
excess of collagen type I, highly cross-linked,
large-diameter ﬁbers, to the detriment of col-lagen type III, essentially non–cross-linked, small-
diameter ﬁbers (4) (Figure 1). Because of the different
biophysical properties of the 2 types of collagen, small
increases in the collagen type I:III content ratio have
been shown to enhance myocardial stiffness. Finally,
changes in collagen organization (i.e., alignment of
collagen ﬁbers relative to the cardiomyocytes), also
seen in myocardial ﬁbrosis, impair the transmission of
the force generated by these cells to the ventricular
chamber, thus exerting a detrimental effect on
myocardial contractility.
Myocardial ﬁbrosis is involved in the pathophysi-
ology and clinical course of cardiac diseases (Figure 1).
In fact, both quantitative and qualitative aspects of
myocardial ﬁbrosis (as evaluated on biopsy samples)
have been shown to be associated with increased left
ventricular (LV) stiffness and diastolic dysfunction
(5), impaired LV contraction and systolic dysfunction
(6), arrhythmias (7), and impaired coronary blood
ﬂow (8) in patients with heart failure (HF) of various
etiologies. In addition, the presence of severe ﬁbrosis
in biopsy samples is reportedly a useful indicator
for long-term mortality in patients with HF (9,10).
Importantly, ﬁbrosis can be seen in the myocardium
of HF patients despite the fact that they are receiving
adequate treatment as recommended by ofﬁcial gui-
delines (5–12). In addition, the extent of ﬁbrosis may
be an important factor in predicting the effectiveness
of long-term HF therapy (e.g., beta-blocker therapy)
(13). Therefore, the assessment of myocardial ﬁbrosis
is important in gaining a better pathophysiologicalunderstanding of the clinical picture, as well as
establishing the prognosis and determining therapy
in patients with HF.
VALIDATION OF A CIRCULATING MOLECULE
AS A BIOMARKER OF MYOCARDIAL FIBROSIS
Any candidate biomarker of myocardial ﬁbrosis must
be compared with the current gold standard for
diagnosis of myocardial ﬁbrosis, which is the histo-
pathological analysis of myocardial tissue. In addition
to its clinical roles, endomyocardial biopsy may be
used as a research tool to better understand the
cellular and molecular pathophysiology of cardiac
diseases, as well as to identify new diagnostic and
therapeutic targets (as reviewed by Cooper et al.
[14]). In this conceptual framework, the identiﬁcation
of a given circulating molecule as a true biomarker
of myocardial ﬁbrosis requires demonstration that
its blood levels directly correlate with quantitative
parameters used to deﬁne ﬁbrosis in endomyocardial
biopsy specimens.
The percentage of total myocardial tissue occupied
by collagen ﬁbers or myocardial collagen volume
fraction (CVF) can be determined with automated
image analysis systems in myocardial samples with
collagen-speciﬁc staining. Similarly, the use of
monoclonal antibodies against collagen type I and
collagen type III allows the determination of the
myocardial CVF occupied by either collagen type I
(CIVF) or collagen type III (CIIIVF) ﬁbers, respectively.
Thus, myocardial ﬁbrosis is characterized by abnor-
mally high values of CVF, CIVF, and CIIIVF and/or
of the ratio of CIVF:CIIIVF (15).
Because of the patchy distribution of myocardial
ﬁbrosis, the greatest potential limitation to endo-
myocardial biopsy evaluation is sampling error.
Therefore, the analysis of several tissue fragments
is important for diagnostic accuracy and interpreta-
tion. A biopsy of the left ventricle may seem diag-
nostically more contributive than a biopsy of the right
ventricle in some cardiomyopathies. However, Pearl-
man et al. (16), using postmortem tissue from cardiac
patients without HF, found that myocardial ﬁbrosis
(assessed as the CVF) is a generalized process similarly
affecting the 2 cardiac chambers. Furthermore, we
reported that ﬁbrosis (assessed as the CVF) present in
biopsy specimens of the right side of the interven-
tricular septum is similar to ﬁbrosis present in the free
wall of the left ventricle in HF patients (17).
Importantly, the endomyocardial biopsy is a safe
procedure. It has a rate of transient complications
of <0.5% and a risk of cardiac perforation with
tamponade of <0.05% (18).
FIGURE 1 Pathophysiology of Myocardial Fibrosis
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Schematic view of the general mechanisms and consequences of myocardial ﬁbrosis. HF ¼ heart failure; LV ¼ left ventricular.
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2451VALIDATION OF THE CANDIDATE BIOMARKERS:
AVAILABLE CLINICAL EVIDENCE
A number of molecules, detectable in either the
serum or plasma in humans by using immunoassay
methods, have recently been proposed as biomar-
kers of myocardial ﬁbrosis (Table 1). However, in
most cases, demonstration of an association between
the biomarker and histologically assessed myocar-
dial ﬁbrosis (i.e., the blood level of the biomarker
directly correlates with either CVF or CIVF or CIIIVF,
and after a therapeutic intervention, it changes in
parallel with the changes in some of these 3 histo-
logical parameters) is lacking or remains inconclu-
sive. Some examples may serve to illustrate the
importance of this initial validation of the candidate
molecules.BIOMARKERS WITH PROVEN EVIDENCE OF THEIR
ASSOCIATION WITH MYOCARDIAL FIBROSIS. As
presented in Table 1, among the many circulating
molecules proposed as biomarkers of myocardial
ﬁbrosis in humans, only 2 collagen-derived serum
peptides have been shown to be associated with
myocardial ﬁbrosis: the carboxy-terminal propeptide
of procollagen type I (PICP), formed during the extra-
cellular conversion of procollagen type I into mature
ﬁbril-forming collagen type I by the enzyme procolla-
gen type I carboxy-terminal proteinase, and the
amino-terminal propeptide of procollagen type III
(PIIINP), formed during the extracellular conversion of
procollagen type III intomatureﬁbril-forming collagen
type III by the enzyme procollagen type III amino-
terminal proteinase (Figure 2). This topic has been
reviewed previously by Prockop and Kivirikko (19).
TABLE 1 Histological Validation of Circulating Molecules Proposed as Biomarkers of
Myocardial Fibrosis in Clinical Studies
Is the Circulating Level of the Molecule
Associated With Histologically Proven
Myocardial Fibrosis?
Molecules related to collagen metabolism
C-terminal propeptide of procollagen type I Yes (6,11,20–23,29)
N-terminal propeptide of procollagen type I Unknown
N-terminal propeptide of procollagen type III Yes (23,24)
C-terminal telopeptide of collagen type I Inconclusive evidence (23,24)
Matrix metalloproteinase-1 No (17)
Matrix metalloproteinase-2 Unknown
Matrix metalloproteinase-3 Unknown
Matrix metalloproteinase-8 Unknown
Matrix metalloproteinase-9 Unknown
Tissue inhibitor of metalloproteinases-1 No (17)
Tissue inhibitor of metalloproteinases-4 Unknown
Molecules related to the regulation of
collagen turnover
microRNA-21 Inconclusive evidence (26)
microRNA-29b Unknown
microRNA-122 Unknown
microRNA-133a Unknown
microRNA-499-5p Unknown
Transforming growth factor-b1 Inconclusive evidence (30,34)
Growth differentiation factor-15 Inconclusive evidence (36)
Connective tissue growth factor Inconclusive evidence (30)
Osteopontin No (30,39)
Osteoglycin Unknown
Syndecan-1 Unknown
Syndecan-4 Unknown
Molecules integrating cardiac stress injury,
inﬂammation, and ﬁbrosis
Galectin-3 Inconclusive evidence (29,30)
Cardiotrophin-1 No (42)
Soluble ST2 Unknown
Midregional pro-atrial natriuretic peptide Unknown
Myostatin Unknown
The supportive references are presented in parentheses.
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2452Serum PICP levels have been found to be highly
correlated with total CVF in patients with hyperten-
sive heart disease (HHD) without (20) and with (6,11)
HF. In addition, it has been shown that there is a
robust correlation between serum PICP levels and
CIVF in patients with HHD and HF (21). Of interest,
serum PICP levels and CVF reportedly changed in
parallel in response to losartan therapy in patients
with HHD without HF (22) and in response to tor-
asemide therapy in patients with HHD and HF (11).
These levels also varied similarly in HF patients with
idiopathic dilated cardiomyopathy (DCM) treated
with spironolactone (23).
Serum PIIINP has been found to be highly cor-
related with CIIIVF in HF patients with ischemic
heart disease or idiopathic DCM (24). In addition,
the reduction in the extent of CVF observed inHF patients with idiopathic DCM treated with
spironolactone was accompanied by a signiﬁcant
reduction in serum PIIINP (23).
BIOMARKERS WITH INCONCLUSIVE EVIDENCE OF
THEIR ASSOCIATION WITH MYOCARDIAL FIBROSIS.
Although the small carboxy-terminal telopeptide
released by the action of matrix metallo-proteinase
(MMP)-1 on collagen type I ﬁbers (CITP) may reﬂect
collagen degradation (20), the information regarding
its relation to myocardial ﬁbrosis is controversial. A
direct correlation of CITP with CIVF was reported in
HF patients with ischemic heart disease or idiopathic
DCM (24); however, Izawa et al. (23) found that serum
CITP levels were lower in HF patients with idiopathic
DCM and severe myocardial ﬁbrosis than in patients
with mild to moderate ﬁbrosis. Furthermore, the
reduction in ﬁbrosis with spironolactone in patients
with severe ﬁbrosis was accompanied by an increase
in serum CITP (23).
It has been shown experimentally that microRNA-21
regulates the activity of cardiac ﬁbroblasts and
participates in the development of myocardial
ﬁbrosis (25). Interestingly, the circulating levels of
microRNA-21 were directly correlated with myocardial
expression of collagen type I messenger ribonucleic
acid in patients with isolated severe aortic stenosis
undergoing aortic valve replacement surgery (26).
However, no data were provided in this study
regarding CVF and CIVF or their potential association
with microRNA-21.
Although the available evidence suggests that the
small lectin-like protein galectin-3 mediates ﬁbrosis
in different experimental models of HF (27,28), no
associations were found between plasma galectin-3
levels and CVF, CIVF, and CIIIVF in patients with
HHD and HF (29). Conversely, even though CVF in-
creased signiﬁcantly in HF patients with idiopathic
DCM 6 months after left ventricular assist device
(LVAD) support, plasma galectin-3 decreased signiﬁ-
cantly in the same patients (30). Although it has been
shown that the matricellular protein connective tis-
sue growth factor is up-regulated in different models
of myocardial ﬁbrosis (31,32), its plasma level did
not correlate with CVF in HF patients with non-
ischemic DCM, and it remained stable 6 months after
LVAD support in these patients, despite the fact
that CVF increased signiﬁcantly (30).
Abundant experimental evidence supports the
notion that transforming growth factor (TGF)-b plays
an important role in the pathogenesis of myocardial
ﬁbrosis (reviewed by Dobaczewski et al. [33]), and
plasma TGF-b levels were found to be directly corre-
lated with the LV myocardial expression of collagen
type I messenger ribonucleic acid in patients with
FIGURE 2 Extracellular Generation and Release Into the Bloodstream of Collagen-Derived Serum Peptides
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(A) The amino-terminal propeptide of procollagen type I (PINP) and the carboxy-terminal propeptide of procollagen type I (PICP) originate
during the conversion of procollagen type I in collagen type I, and (B) the amino-terminal propeptide of procollagen type III (PIIINP) and the
carboxy-terminal propeptide of procollagen type III (PIIICP) originate during the conversion of procollagen type III in collagen type III. (1) Since
PICP is formed in a 1:1 stoichiometric ratio to the collagen type I molecule formed, the propeptide concentrations in tissue ﬂuids and blood are
direct indicators of ongoing collagen type I synthesis. (2) The cleavage at the amino-terminus proceeds at a relatively slow rate and, thus,
partially processed procollagen molecules (known as pN-collagen type III molecules) are found on the surface of collagen type III ﬁbers.
Therefore, the PIIINP concentrations in tissue ﬂuids and blood are not direct indicators of ongoing collagen type III synthesis. (3) Although PIIICP
is set free, it is unknown whether it reaches the bloodstream. PICP ¼ procollagen type I carboxy-terminal proteinase; PINP ¼ procollagen type I
amino-terminal proteinase; PIIICP ¼ procollagen type III carboxy-terminal proteinase; PIIINP ¼ procollagen type III amino-terminal proteinase.
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However, no correlation of plasma TGF-b with either
CVF or CIVF was provided in this study. In addition, it
has been reported that plasma TGF-b levels were
higher in control subjects than in HF patients with
idiopathic DCM that had abnormally high CVF values
(30). Furthermore, although CVF increased signiﬁ-
cantly in these patients 6 months after LVAD support,
plasma TGF-b did not change.
Growth differentiation factor-15 is a member of the
TGF-b cytokine superfamily that has been shown tobe associated with myocardial ﬁbrosis in a genetic
model of HF (35). Although plasma levels of growth
differentiation factor-15 reportedly correlate directly
with CVF in patients with idiopathic DCM before
LVAD support, the reduction in these levels observed
1 month after LVAD support was accompanied by an
increase in CVF (36).
BIOMARKERS WITH LACK OF EVIDENCE OF THEIR
ASSOCIATION WITH MYOCARDIAL FIBROSIS. No
correlations between CVF and serum MMP-1, serum
tissue inhibitor of matrix metalloproteinases-1, and
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2454their ratio (which may serve as an indirect index of
circulating unbound active MMP-1) have been found
in patients with HHD and HF (17). However, it is
noteworthy that those patients with higher values of
serum MMP-1 and serum MMP-1:tissue inhibitor of
matrix metalloproteinases-1 ratio exhibited reduced
levels of perimysial and endomysial collagen. This
ﬁnding suggests that these molecules may be related
more to the loss of the physiological mysial collagen
scaffold than to the accumulation of pathologic non-
mysial collagen.
Experimental ﬁndings support the notion that the
matricellular protein osteopontin seems to mediate
ﬁbrogenic actions in HF models (37,38). However,
plasma concentrations of osteopontin are reportedly
not associated with CVF or CIVF in patients with HHD
and HF (39). Furthermore, in HF patients with non-
ischemic DCM, plasma osteopontin levels tended to
decrease whereas CVF increased signiﬁcantly during
LVAD support (30).
Cardiotrophin-1 is a member of the interleukin-6
superfamily that behaves in vitro as a proﬁbroticTRATION Process for the Clinical Validation of a
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ﬁbroblasts (40), and in vivo it induces cardiac
ﬁbrosis in rats (41). Recently, an association between
the myocardial expression of cardiotrophin-1 and
collagen types I and III has been reported in the
ﬁbrotic myocardium of patients with HF of hyper-
tensive origin (42). However, the plasma levels of
cardiotrophin-1 were not correlated with CVF, CIVF,
or CIIIVF in the same patients.
LESSONS TO LEARN FROM THE
AVAILABLE EVIDENCE
It is necessary to be cautious when translating
experimental data into the clinical setting. In fact,
although the experimental ﬁndings may support a
causative role for a given molecule in the develop-
ment of myocardial ﬁbrosis, this does not mean that
in cardiac patients, the molecule’s circulating levels
will mirror the extension and severity of the myocar-
dial deposition of collagen ﬁbers. However, it is
important to note that due to the nature of the clinical
investigations reviewed here, the information pro-
vided in most of the studies is more of a snapshot of
the evolutionary state of cardiomyopathy rather than
a view on the progression of the pathologic process.
Although the endomyocardial biopsy procedure is
safe, the difﬁculty in performing it in clinical practice
for research purposes must be recognized. The use of
noninvasive methods as an alternative should thus
be considered. In this regard, the ability to non-
invasively examine the myocardium by using cardiac
magnetic resonance imaging could also be useful
for the initial validation of circulating biomarkers of
myocardial ﬁbrosis. Despite restricted accessibility,
cardiac magnetic resonance imaging is emerging as a
modality that enables noninvasive evaluation of the
myocardial interstitial space through the measure-
ment of myocardial extracellular volume with T1
mapping techniques. Interestingly, it has been shown
in patients with various cardiac diseases that cardiac
magnetic resonance–measured myocardial extracel-
lular volume correlates with CVF (as reviewed by
Treibel et al. [43]). However, T1 mapping is evolving
rapidly and still requires methodological standardi-
zation. Therefore, although accumulation of ﬁbrotic
tissue leading to expansion of the interstitial space
may be partly responsible for the increase in the
extracellular volume, whether this measurement can
serve as a surrogate parameter of myocardial ﬁbrosis
for validation purposes of a candidate circulating
biomarker requires further investigation.
The interpretation of the serum levels of the 2
biomarkers with proven evidence of its association
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plex issue that deserves some consideration. First,
their tissue and organ origin are still unclear. For
instance, a net release of PICP (6), but not of PIIINP
(44), from the heart has been reported in patients
with HF. In addition, whereas some authors have
found a net release of PIIINP from the heart in pa-
tients with aortic stenosis (45), others failed to ﬁnd
such a release in patients with the same cardiac valve
disease (44), patients with hypertrophic cardiomy-
opathy (46), and HF patients with ischemic heart
disease or idiopathic DCM (47). Second, the diag-
nostic usefulness of these biomarkers may vary
among cardiac diseases. In fact, whereas the associ-
ation between serum PICP and CIVF was observed in
HF patients with HHD (6,21) but not in HF patients
with ischemic heart disease or idiopathic DCM (24),
the opposite was true for serum PIIINP and CIIIVF
(6,21,24). Third, changes in serum concentrations of
these biomarkers in patients with cardiovascular
diseases may represent integrated abnormalities
of the cardiovascular collagen (e.g., an excess of
collagen types I and III is present in the arterial
wall of hypertensive patients with arterial stiffness).
Fourth, the presence of concomitant noncardiac
diseases affecting collagen metabolism may also
affect the circulating levels of these molecules (48).
This ﬁnding may be highly relevant in conditions
involving chronic liver insufﬁciency (because PICP
and PIIINP are cleared via uptake by endothelial cells
in the liver) and in the setting of metabolic bone
diseases with high collagen type I turnover.
Finally, as demonstrated experimentally (49) and
clinically (21,50), the effects of an increase in collagen
quantity on LV hemodynamics are modiﬁed not only
by the relative abundance of collagen type I over
collagen type III but also by the degree of collagen
cross-linking among the ﬁbrils forming the ﬁber.
Therefore, to have a more global idea of how
myocardial ﬁbrosis inﬂuences cardiac function, bio-
markers assessing the quality of the myocardial
network are also necessary.CLINICAL IMPLICATIONS
Cardiac diseases evolving with HF in which myocar-
dial ﬁbrosis is a determinant of outcome represent a
major disease burden and, in many cases, their preva-
lence is increasing. Therefore, the investigation of
circulating biomarkers to trackmyocardialﬁbrosis needs
to beamajor focus in the comingyears. In this conceptual
framework, the candidate biomarker must be initially
tested to see whether it robustly reﬂects myocardial
ﬁbrosis (Central Illustration). If this is the case, then it
must be tested to seewhether it possesses addedvalue in
terms of diagnosis, prognosis, and therapeutic moni-
toring when compared to the available biomarkers
(Central Illustration). For the ﬁrst step, the application of
speciﬁc protocols aimed to assess associations of
biomarker levels with histological (or cardiac magnetic
resonance) parameters of myocardial ﬁbrosis is manda-
tory. Additionally, the use of panels combining imaging
and circulating biomarkersmay integrate different levels
of information, overcome methodological limitations,
and contribute to a better proﬁling of each individual
patient with a view to personalize the therapy.
To develop strategies aimed to validate biomarkers
of myocardial ﬁbrosis useful in the clinical handling of
cardiac patients, collaboration between academia, in-
dustry, and government agencies is required. This joint
effort should result in the creation of consortia that
would allow the identiﬁcation of a comprehensive
panel of circulating (and imaging) biomarkers of
myocardial ﬁbrosis to be concomitantly analyzed in a
pooled sample of randomized, hypothesis-driven clin-
ical trials. The success of these initiatives will depend
on circulating biomarkers for myocardial ﬁbrosis being
successfully incorporated into day-to-day clinical
practice, thus contributing to achievements in person-
alized medicine in the cardiologic domain.
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